Vivimed Labs Ltd / Active e Pharma a Brande nded Speci cialt alty Ingred edien ent Formulat ations ns Chemical cals Investor Presentation February 2018 1 1
Safe Harbor / This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vivimed Labs Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward- looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. 2
Consolidated Performance Highlights / Revenue* EBITDA* Net Profit* 19.6% 19.8% 6.2% 7.4% 1258.1 246.2 85.2 66.9 178.0 900.1 FY17* 9MFY18 FY17* 9MFY18 FY17* 9MFY18 Margins% 3 *Normalized for one time gain from sale to Klarsen and Clariant Figures in Rs. Crores, as per IndAS
Segmental Information / 17.2% 12.4% 21.2% 32.4% 236.7 788.5 Revenue 748.6 Specialty Pharmaceuticals 151.5 Chemicals 9MFY17 9MFY18 9MFY17 9MFY18 EBIT Margins% Sp Specia ialt lty Che Chemic icals ls: 1. The 9MFY17 figures also include the sales from the segments which were divested to Clariant ( India) Ltd. while the 9MFY18 figures are of the segment as it exists today 2. The hair dyes segment has witnessed 22.3% % Y-O-Y Y gr growt wth and photochromics witnessed 65.0% % Y-O-Y gr growt wth, in GBP terms Pha harmaceutic icals ls: 1. The FDF segment of the Pharma in 9MFY17 had included sales of business divested to Klarrsen, while the 9MFY18 results are of the residual segment 2. The drop in margins is a result of considerable increase in prices of a key raw material being sourced from China 3. Company’s strong track record of regulatory compliance has provided a competitive edge. It has been a differentiator for both the CMO & Generic businesses and helped drive the sales and the order book 4 Figures in Rs. Crores, as per IndAS
Reducing Debt in the Company / Debt (in Rs. Crs) -212 1006 926 794 Mar-17 Sep-17 Dec-17 Vivimed has been focused towards debt reduction and reducing the cost of funds # Consolidated Figures, as per IND AS 5
Business on a Growth Track / Formulations API Specialty Chemicals • Joint Venture agreement with M/s • Orbimed Asia III Mauritius Limited has • Demand in the basic and Oxidatives Strides Shasun Ltd, to ensure full invested USD 50mn. The funds are being dyes, showing a marked increase utilization of Allathur Plant. Expect, the utilized for the purpose of: • Photochromics continues to be on its JV contribution to flow in from FY19 • Invest in API business for Capacity growth path in Optical segment. And it onwards Augmentation and Organic Growth has found applications in other segments • Successful registration of 8 products in as well • Generics Segment is introducing new anti viral, pain management and cough products in the coming years, and the • Moving towards a Joint venture with a suppressants segment, post certification right balance between API products and Japanese company for a photochromic by Ukraine FDA for unit 1 located in CDMO operations is being maintained molecule for applications in Optical Hyderabad segment • Distribution agreement with ‘Alter Ego • Other Chemicals continue to grow at a LLC’, for distributing its products in steady pace Ukraine, Russia and other CIS regions. Expects revenue upwards of 10million USD in FY19 6
Vivimed Labs at a Glance / Global supplier of niche molecules and formulations across Pharmaceuticals and Specialty Chemicals Pharmaceuticals: Present across the critical components in the value chain US FDA approved world class manufacturing facilities Leveraging India based R&D for competitive advantage Targeting ROW markets through PICS approved FDF plants Blue chip Customer base strengthened by partnership model Strong management team with rich and diverse industry experience 7
Business Divisions / Revenue Break Up as of 9M FY2018 • Uquifa s.a. is the Spanish subsidiary of Vivimed Labs with 80 years of experience having US FDA approved manufacturing units in Spain (2) and Mexico (1) • Manufactures APIs for pharmaceutical and animal health industries globally API • It has over 40 type 2 DMF filed with US FDA and more than 150 active DMF’s (UQUIFA) worldwide Specialty • Chemical Uquifa’s CDMO business has experienced exponential growth due to strong R&D s, 16.8% global team, emerging products, and partnerships with global players such as GSK, Pfizer, Gillead, Esteve, etc. • A value added business that delivers quality formulations and offers novel drug Pharmaceuticals, systems 83.2% • Pharma Present in generic, branded and contract manufacturing segments • Focus to expand into the non-USA based regulated generic markets such as the CIS FDF and African Countries • Manufactures Hair Dyes, Photochromic Dyes, Anti-Microbials and Imaging Chemicals Pharmaceuticals Specialty Chemicals • Vivimed is a world leader in the development of innovative photochromic dyes Specialty • Vivimed has patented processes for novel dyes targeting a range of applications Chemicals 8
Multinational Global Platform / Faci acilities Tot otal Pharmaceuticals – API 3 Pharmaceuticals – FDF 7 Kas ashipur Specialty Chemicals - Active Har aridwar 1 Ingredients Tot otal Faci acilities 11 11 San Sant Cel eloni, , Spa Spain R&D Facilities 6 Lliçà de Lliç de Vall all, Spai Spain Kolkata Global Support Offices 5 Cuernavaca, , Mexico Bid idar Bol olarum Jeedimetla (2) (2) Alathur Ala 11 11 man anufacturing facil acilities s alo along with ith R& R&D D ce centres s and and glo global sup support of offi fices s pr provides s acc access ss to o di diverse mar arkets s and and cos ost adv advantage Map not to Scale 9
Global Clientele / Preferred Su Suppli lier to o the the lead eadin ing globa global l br brands 10
Recommend
More recommend
